ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0628

Higher Quality of Care for Patients with Systemic Lupus Erythematosus in a Subspecialty Lupus Clinic: A Multi-Setting Cross-Sectional Study

Sidha Sreedharan1, Ning Li1, Geoffrey Littlejohn1, Russell Buchanan2, Mandana Nikpour3, Eric Morand4, Alberta Hoi5 and Vera Golder6, 1Monash University, Melbourne, Australia, 2Austin Health, Heidelberg, Melbourne, Australia, 3University of Melbourne at St Vincent's Hospital, Melbourne, Australia, 4School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, 5Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, 6Monash University, Clayton, Australia

Meeting: ACR Convergence 2021

Keywords: Quality Indicators, quality of care, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Title: Measures & Measurement of Healthcare Quality Poster (0623–0659)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Healthcare quality for systemic lupus erythematosus (SLE) is a modifiable target for improving patient outcomes. Disease-specific subspecialty lupus clinics may offer experienced healthcare professionals, collaborative multidisciplinary teams and streamlined care processes. Superior performance of a subspecialty lupus clinic in the provision of quality care has been shown in the United States, where access to care based on insurance status is a major factor. We aimed to compare quality of care provided in a subspecialty lupus clinic with hospital and private general rheumatology clinics in a universal healthcare setting.

Methods: Patients with SLE (n = 258) were recruited in 2016 from various clinic settings in Australia, including a subspecialty lupus clinic (n = 147), two hospital general rheumatology clinics (n = 56) and two private rheumatology clinics (n = 55). Quality of care was assessed using 31 validated SLE quality indicators (QI) encompassing diagnostic work-up, disease and comorbidities assessment, drug monitoring, preventative care and reproductive health. Data were collected from both medical records and patient questionnaires. Overall QI performance was calculated as a percentage of the number of QIs met relative to the number of eligible QIs for each patient. Individual QI performance was measured as a percentage of the number of patients that met the QI relative to the number of patients eligible. Overall and individual QI performance were compared between the three clinic settings, and multivariable regression performed to adjust for sociodemographic, disease and healthcare factors.

Results: QI performance was generally high across clinic types for diagnostic work-up, comorbidity assessment, lupus nephritis, drug monitoring, prednisolone taper, osteoporosis management and pregnancy QIs. However, median [IQR] overall performance on eligible QIs was higher in the lupus clinic (66.7% [57.1-74.1]) than the hospital general rheumatology (52.7% [47.5-58.1]) and private rheumatology (50.0% [42.9-60.9]) clinics (p < 0.01) and remained significant after multivariable adjustment. The subspecialty lupus clinic significantly outperformed the other clinic settings on eligible individual QIs for disease activity, disease damage, cardiovascular risk factor and drug toxicity assessments, pre-immunosuppression hepatitis and tuberculosis screening, new medication counselling, vaccinations, sun avoidance education and contraception counselling.

Conclusion: SLE patients managed in a subspecialty lupus clinic received higher quality of care compared to hospital and private general rheumatology clinics.


Disclosures: S. Sreedharan, None; N. Li, None; G. Littlejohn, AstraZeneca, 1, MSD, 1, AbbVie, 1, Janssen, 1, Pfizer, 1, Seqirus, 1; R. Buchanan, None; M. Nikpour, None; E. Morand, Amgen, 2, AbbVie, 2, Biogen, 2, Bristol Myers Squibb, 2, 5, AstraZeneca, 2, 5, 6, Genentech, 2, Servier, 2, Capella Biosciences, 2, Eli Lilly, 5, 6, EMD Serono, 5, 6, Janssen, 2, 5, UCB, 2, GlaxoSmithKline, 2, 5; A. Hoi, AstraZeneca, 2, 5, Janssen, 6, Abbvie, 6; V. Golder, None.

To cite this abstract in AMA style:

Sreedharan S, Li N, Littlejohn G, Buchanan R, Nikpour M, Morand E, Hoi A, Golder V. Higher Quality of Care for Patients with Systemic Lupus Erythematosus in a Subspecialty Lupus Clinic: A Multi-Setting Cross-Sectional Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/higher-quality-of-care-for-patients-with-systemic-lupus-erythematosus-in-a-subspecialty-lupus-clinic-a-multi-setting-cross-sectional-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/higher-quality-of-care-for-patients-with-systemic-lupus-erythematosus-in-a-subspecialty-lupus-clinic-a-multi-setting-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology